Boehringer Ingelheim
Boehringer Ingelheim is Germany's largest privately-owned pharmaceutical company, headquartered in Ingelheim am Rhein. As a family-owned company reinvesting a significant portion of revenues into R&D, Boehringer Ingelheim has built a reputation for sustained investment in underserved disease areas. The company's research priorities include cardio-renal-metabolic disease, respiratory medicine and immunology, oncology, and neurological conditions. Boehringer Ingelheim was among the first to launch an SGLT2 inhibitor (empagliflozin/Jardiance, developed with Eli Lilly), and remains one of the most active sponsors of cardiorenal trials globally.
Empagliflozin's clinical trial program — the EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY, and ongoing trials — has established SGLT2 inhibition as a cardiovascular and renal protective drug class across heart failure with reduced and preserved ejection fraction, chronic kidney disease (with and without diabetes), and type 2 diabetes. These findings have changed international treatment guidelines and spawned dozens of combination and mechanism-extension trials. Boehringer Ingelheim also co-developed nintedanib (Ofev), the leading anti-fibrotic for idiopathic pulmonary fibrosis and systemic sclerosis-associated ILD.
In oncology, Boehringer Ingelheim runs active trials on afatinib (Gilotrif) in EGFR-mutant NSCLC, investigational bispecific antibodies, and KRAS inhibitor combinations. The immunology and respiratory pipeline features active trials on spesolimab (an IL-36 receptor inhibitor) for generalized pustular psoriasis — an ultra-rare and life-threatening skin condition for which spesolimab received breakthrough designation — and dupilumab-class cytokine programs for asthma and atopic disease. Boehringer Ingelheim operates research sites across 130 countries.